11:07 AM EDT, 09/08/2025 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) said Monday that Voxzogo showed positive impact on spinal morphology in children with achondroplasia based on data from studies.

A mid-stage study found that children on Voxzogo for 52 weeks saw measurable improvement in interpedicular distance and greater spinal canal width in all five vertebrae in the lower back compared with children on placebo, it said.

BioMarin also said that Voxzogo continued to significantly improve growth in children with achondroplasia after puberty onset based on a phase 3 long-term extension study.

Shares of the company were down over 2% in recent trading.

Price: 56.23, Change: -1.54, Percent Change: -2.67